These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11378657

  • 1. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells.
    Nader HB, Pinhal MA, Baú EC, Castro RA, Medeiros GF, Chavante SF, Leite EL, Trindade ES, Shinjo SK, Rocha HA, Tersariol IL, Mendes A, Dietrich CP.
    Braz J Med Biol Res; 2001 Jun; 34(6):699-709. PubMed ID: 11378657
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D, Walenga JM, Fareed J.
    Thromb Res; 1990 Nov 01; 60(3):191-200. PubMed ID: 2084948
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi. An ideal antithrombotic agent?
    Rocha HA, Moraes FA, Trindade ES, Franco CR, Torquato RJ, Veiga SS, Valente AP, Mourão PA, Leite EL, Nader HB, Dietrich CP.
    J Biol Chem; 2005 Dec 16; 280(50):41278-88. PubMed ID: 16174777
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47-kda protein from vascular endothelial cell surface and stimulate the synthesis and structural changes of heparan sulfate proteoglycan.
    Pinhal MA, Trindade ES, Fareed J, Dietrich CP, Nader HB.
    Thromb Res; 2001 Jul 01; 103(1):35-45. PubMed ID: 11434944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
    Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A.
    J Clin Invest; 1998 Feb 15; 101(4):877-89. PubMed ID: 9466983
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates.
    Hovingh P, Piepkorn M, Linker A.
    Biochem J; 1986 Jul 15; 237(2):573-81. PubMed ID: 2948492
    [Abstract] [Full Text] [Related]

  • 17. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells.
    Nader HB, Buonassisi V, Colburn P, Dietrich CP.
    J Cell Physiol; 1989 Aug 15; 140(2):305-10. PubMed ID: 2745565
    [Abstract] [Full Text] [Related]

  • 18. Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro.
    Møller AV, Jørgensen SP, Chen JW, Larnkjaer A, Ledet T, Flyvbjerg A, Frystyk J.
    Eur J Endocrinol; 2006 Aug 15; 155(2):297-305. PubMed ID: 16868144
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD.
    Semin Hematol; 1997 Oct 15; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.